Product Name:
SRPK1-pS222
Product Number:
ab-pk819
Target Full Name: Serine/arginine-rich protein-specific kinase 1; SRPK1a protein kinase
Target Alias: SFRS protein kinase 1; SFRSK1; SRPK1a protein kinase
Product Type Specific: SRPK1 protein kinase phosphosite-specific antibody
Antibody Code: PK819
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S222
Protein UniProt: Q96SB4
Protein SigNET: SRPK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human SRPK1 sequence peptide Cat. No.: PE-04APR99
Antibody Immunogen Sequence: ILG(pS)DDD(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues I219 to D225; Near the N-terminus of the kinase.S222 phosphorylation stimulates phosphotransferase activity. This is a major site of in vivo phosphorylation of SRPK1 based on ≥71 mass spectrometry reports recorded in PhosphoSitePlus. In PhosphoSitePlus, this phosphosite is listed as S51. SRPK1 is known to be phosphorylated at this site in vitro by CK2a1 (CSNK2A1), and CK2a2 (CSNK2A2).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Mouse | Frog.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 90-100 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: In HeLa cells, phenylarsine oxide (PAO) increases detection of 80 and 75 kDa proteins. No cross-reactivities observed in T98G cells.
Related Product 1: SRPK1 (219-225) pS222 antibody blocking peptide (Cat. No.: PE-04APR99)
Related Product 2: SRPKSubtide kinase substrate peptide (Cat. No.: PE-01BJL95)
Related Product 3: SRPK1 S587 phosphorylation antibody (Cat. No.: AB-PK891)
Related Product 4: SRPK2 expression antibody (Cat. No.: AB-NK296-1)
Scientific Background: SRPK1 (Serine-arginine protein kinase 1; SFRSK1) is a protein-serine/threonine kinase of the CMGC group and SRPK family. It is a highly conserved, constitutive enzyme that specifically phosphorylates serine-arginine (SR)-rich splicing factors (e.g., SRSF1 (ASF/SF2, SC35, and SRp55), essential for mRNA processing, and controlling their localization and activity in the nucleus. It plays an important role in regulating alternative splicing, cell survival, and tumour angiogenesis. It regulates angiogenesis (VEGF-A165/VEGF-A165b balance) and is involved in HIV-1 viral core phosphorylation. This kinase is moderate to highly expressed in most tested human tissues except apparently in the brain and spinal cord. It featuresf two kinase domains separated by a distinct spacer region. SRPK1 is activated by phosphorylation at Ser-51 and Ser-555. Elevated SRPK1 expression is linked to tumour growth, metastasis, and poor prognosis in many cancers by activating paths like PI3K/AKT, NF-κB, and Wnt/β-catenin. In human cancer cells, it was observed that inactivation of SRPK1 induces cellular resistance to anticancer drugs such as cisplatin and bleomycin. This description may include information annotated by UniProt and/or Google AI.